基于肌酐估算肾小球滤过率的遗传风险评分与肾脏结局的关联评估
在PREVEND社区队列3649人中,基于53个eGFRcrea相关SNP构建的遗传风险评分与基线eGFRcrea较低及CKD患病率较高独立相关,与CKD发病率相关但校正基线eGFR后不再显著,且与eGFR下降无关;与胱抑素C估算结局关联相似。
要点
- 遗传风险评分与基线CKD患病和eGFR水平独立相关。
- 与CKD发病的关联可能归因于基线eGFR较低,而非eGFR加速下降。
- 基于eGFRcrea的评分可能反映肾功能遗传基础,而非肌酐代谢。
核心结论
- 遗传风险评分与基线CKD和eGFR独立相关,与CKD发病的关联可能由基线eGFR较低所致,而非eGFR加速下降。
研究设计与样本
- 基于社区队列PREVEND研究,纳入3649名受试者,中位年龄49岁,52%男性,中位随访11年。
- 遗传风险评分由53个eGFRcrea相关SNP按报道效应量加权构建,校正基线人口学和肾脏危险因素。
主要发现
- 基线时,遗传风险评分较高与eGFRcrea较低相关,校正B(95%CI)为-2.05(-2.45至-1.65)mL/min/1.73 m2,P<0.001。
- 基线时,遗传风险评分较高与CKD患病率较高相关,校正OR(95%CI)为1.41(1.12-1.77),P=0.002。
- 随访期间,遗传风险评分较高与CKD发病率较高相关,校正HR(95%CI)为1.28(1.09-1.50),P=0.004,但校正基线eGFR后不再显著。
- 未发现与eGFRcrea下降显著相关,与胱抑素C估算结局的关联相似。
临床怎么用
- 遗传风险评分可用于识别基线CKD高风险个体,但尚不能预测eGFR下降轨迹。
- 临床解读遗传风险评分时应结合基线eGFR,而非单独用于预测CKD发病。
局限性
- 研究基于社区队列,结果外推需谨慎。
- 遗传风险评分仅纳入53个eGFRcrea相关SNP,未涵盖其他肾功能相关位点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Meta-analysis of cross-sectional genome-wide association studies (GWAS) on creatinine-estimated glomerular filtration rate (eGFRcrea) identified 53 single-nucleotide polymorphisms (SNPs). These SNP effects can be aggregated into a genetic risk score (GRS) for chronic kidney disease (CKD). To assess its clinical utility, we examined associations with creatinine-estimated kidney outcomes, both cross-sectionally and longitudinally. Additionally, we examined associations with cystatin C-estimated kidney outcomes to verify that a GRS based on eGFRcrea SNPs represents the genetics underlying kidney function. METHODS: In the community-based Prevention of REnal and Vascular ENdstage Disease (PREVEND) study, we assessed eGFRcrea and eGFRcysc at baseline and four follow-up examinations. The GRS comprised 53 SNPs for eGFRcrea weighted for reported effect-sizes. We adjusted for baseline demographics and renal risk factors. RESULTS: We included 3649 subjects (median age 49 years, 52% male, median follow-up 11 years, n = 85 baseline CKD, n = 154 incident CKD). At baseline, a higher GRS associated with lower eGFRcrea {adjusted B [95% confidence interval (CI)] = -2.05 (-2.45 to - 1.65) mL/min/1.73 m2, P < 0.001} and higher CKD prevalence [adjusted odds ratio (95% CI) = 1.41 (1.12-1.77), P = 0.002]. During follow-up, a higher GRS associated with higher CKD incidence [adjusted hazard ratio (95% CI) = 1.28 (1.09-1.50), P = 0.004], but no longer significantly after adjustment for baseline eGFR. No significant association with eGFRcrea decline was found. Associations with cystatin C-estimated outcomes were similar. CONCLUSIONS: The GRS robustly associated with baseline CKD and eGFR, independent of known risk factors. Associations with incident CKD were likely due to low baseline eGFR, not accelerated eGFR decline. The GRS for eGFRcrea likely represents the genetics underlying kidney function, not creatinine metabolism or underlying aetiologies. To improve the clinical utility of GWAS results for CKD, these need to specifically address eGFR decline and CKD incidence.
引用
- Thio CHL, van der Most PJ, Nolte IM, et al. Evaluation of a genetic risk score based on creatinine-estimated glomerular filtration rate and its association with kidney outcomes. Nephrol Dial Transplant. 2018. PMID: 29294079. doi:10.1093/ndt/gfx337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。